During the Investors Forum fourteen young companies had the opportunity to present their company to interesting partners and discuss their business strategy, technology direction and capital-raising plan.
On stage of the 15th edition of the Dutch Life Sciences Conference, AGILeBiotics became the proud winner of the Progress Investors Forum Prize. The Venture Challenge alumnus was awarded a partnering ticket, national or international, with a total value of €2,500.
Empowering antibiotic development
During the conference AGILeBiotics has introduced its drug pipeline emphasizing the pre-clinical candidate TOFRAMICIN, a novel antibiotic candidate in development against multidrug-resistant Gram-negative and Gram-positive bacterial infections. With their plenary pitch, they have successfully reached out to potential co-investors in order to close the Series A round in near future. The investment will bring TOFRAMICIN into clinical development and closer to patients suffering from deadly hospital-acquired infections.
Investors Forum
The Investors forum is an exciting opportunity for those young companies (< 5 years) looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, medtech and pharma companies to financiers and universities.
If you are interested in participating in the Investors Forum 2020, please contact Miranda de Regt at miranda.de.regt@dutchlifesciences.com.
Venture Challenge Spring 2020: Call open!
Our specialised coaching focuses on developing your initial idea into a solid business during a series of boot camps and 1-on-1 coaching and mentoring sessions. Startup teams learn to identify key risks, analyse customer value propositions, develop a validation strategy, learn to build a venture plan and, ultimately, get connectedto Life Sciences experts, investors and seasoned entrepreneurs. Read more